Clinical Trial: NCT05553834
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Duke University |
| Information Provided By: | Duke University |
| Last Update Posted: | 2026-04-13 |
Study Overview
Brief Summary
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
Official Title
Conditions
Intervention / Treatment
- Combination Product: Alirocumab and Cemiplimab
Other Study ID Numbers
- PRO00111111
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Duke University |
| Information Provided By: | Duke University |
| Last Update Posted: | 2026-04-13 |
Study Overview
Brief Summary
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
Official Title
Conditions
Intervention / Treatment
- Combination Product: Alirocumab and Cemiplimab
Other Study ID Numbers
- PRO00111111